Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynette M Moore

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Opinion on Therapeutic Targets|October 15, 2010
Targeting miR-21 in glioma: a small RNA with big potentialLynette M Moore, Wei Zhang
Chinese Journal of Cancer|March 1, 2011
Oncogene interactions are required for glioma development and progression as revealed by a tissue specific transgenic mouse modelLynette M Moore, Kristen M Holmes, Gregory N Fuller, et al.
Neuro-Oncology|July 24, 2013
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in gliomaChunzhi Zhang, Lynette M Moore, Xia Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomasLynette M Moore, Kristen M Holmes, Sarah M Smith, et al.
The Journal of Pathology|September 26, 2012
Transcriptome and small RNA deep sequencing reveals deregulation of miRNA biogenesis in human gliomaLynette M Moore, Virpi Kivinen, Yuexin Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2012
Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB networkKristen M Holmes, Matti Annala, Corrine Y X Chua, et al.
Oncogene|April 22, 2014
Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastomaXia Li, Yuexin Liu, Kirsi J Granberg, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Opinion on Therapeutic Targets|October 15, 2010
Targeting miR-21 in glioma: a small RNA with big potentialLynette M Moore, Wei Zhang
Chinese Journal of Cancer|March 1, 2011
Oncogene interactions are required for glioma development and progression as revealed by a tissue specific transgenic mouse modelLynette M Moore, Kristen M Holmes, Gregory N Fuller, et al.
Neuro-Oncology|July 24, 2013
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in gliomaChunzhi Zhang, Lynette M Moore, Xia Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomasLynette M Moore, Kristen M Holmes, Sarah M Smith, et al.
The Journal of Pathology|September 26, 2012
Transcriptome and small RNA deep sequencing reveals deregulation of miRNA biogenesis in human gliomaLynette M Moore, Virpi Kivinen, Yuexin Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2012
Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB networkKristen M Holmes, Matti Annala, Corrine Y X Chua, et al.
Oncogene|April 22, 2014
Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastomaXia Li, Yuexin Liu, Kirsi J Granberg, et al.
Pageof 1